You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Suppliers and packagers for HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%


✉ Email this page to a colleague

« Back to Dashboard


HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% heparin sodium INJECTABLE;INJECTION 017029 NDA Henry Schein, Inc. 0404-9979-01 1 VIAL, MULTI-DOSE in 1 BAG (0404-9979-01) / 1 mL in 1 VIAL, MULTI-DOSE 2022-01-17
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% heparin sodium INJECTABLE;INJECTION 017029 NDA HF Acquisition Co LLC, DBA HealthFirst 51662-1409-1 5 mL in 1 VIAL (51662-1409-1) 2019-11-11
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% heparin sodium INJECTABLE;INJECTION 017029 NDA HF Acquisition Co LLC, DBA HealthFirst 51662-1409-3 25 POUCH in 1 CASE (51662-1409-3) / 1 VIAL in 1 POUCH (51662-1409-2) / 5 mL in 1 VIAL 2019-11-11
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% heparin sodium INJECTABLE;INJECTION 017029 NDA HF Acquisition Co LLC, DBA HealthFirst 51662-1578-1 250 mL in 1 BAG (51662-1578-1) 2021-07-15
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% heparin sodium INJECTABLE;INJECTION 017029 NDA Cardinal Health 107, LLC 55154-9583-5 5 VIAL in 1 BAG (55154-9583-5) / 10 mL in 1 VIAL 2019-11-04
Fresenius Kabi Usa HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% heparin sodium INJECTABLE;INJECTION 017029 NDA Cardinal Health 107, LLC 55154-9585-5 5 VIAL in 1 BAG (55154-9585-5) / 1 mL in 1 VIAL 2020-03-25
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Heparin Sodium 25,000 Units in Sodium Chloride 0.45%

Last updated: August 4, 2025


Introduction

Heparin sodium, a widely utilized anticoagulant, plays a crucial role in clinical settings ranging from perioperative prophylaxis to treatment of thromboembolic disorders. Specifically, Heparin Sodium 25,000 Units in Sodium Chloride 0.45% often caters to institutional use, requiring large-volume formulations with strict manufacturing and regulatory standards. Identifying reliable suppliers is essential for healthcare providers, pharmaceutical companies, and distributors to ensure consistent quality, regulatory compliance, and supply chain security.

Market Overview

The global heparin market reflects robust demand driven by surgical procedures, dialysis, and acute care applications. The primary production of pharmaceutical-grade heparin occurs through controlled extraction from porcine intestines, necessitating strict sourcing protocols. Multiple suppliers operate within this framework, adhering to Good Manufacturing Practices (GMP), FDA, EMA, and other regulatory standards.

Leading Suppliers of Heparin Sodium 25,000 Units in Sodium Chloride 0.45%

1. Baxter International Inc.

Baxter is a prominent manufacturer and supplier of injectable anticoagulants, including heparin products. Their Heparin Sodium 25,000 Units in Sodium Chloride 0.45% is produced under stringent GMP standards, approved by major regulatory authorities such as the FDA, EMA, and Health Canada.

Product Features:

  • Available in prefilled syringes, vials, and infusion bags
  • Consistent potency and purity
  • Extensive distribution network globally

Market Presence: Baxter’s global footprint ensures reliable supply chains, with manufacturing facilities compliant with international standards.

2. Pfizer Inc. (Hospira)

Hospira, now part of Pfizer, specializes in provider-centric injectable drugs. Its Heparin Sodium solutions are reputed for high quality, supported by rigorous quality control protocols, with FDA approval and international certifications.

Product features:

  • Various concentration forms including 25,000 Units in 0.45% sodium chloride
  • Compatibility with infusion systems
  • Proven stability and safety profile

Distribution: Pfizer’s extensive distribution system ensures product availability worldwide, including North America, Europe, and Asia.

3. Sano Chemical Industries

An India-based pharmaceutical manufacturer, Sano Chemical Industries produces high-quality heparin sodium batches supplied internationally. Their products adhere to pharmacopoeial standards, including USP and BP.

Notable attributes:

  • Competitive pricing
  • Custom packaging options
  • Compliance with global regulatory requirements

Markets served: Middle East, Southeast Asia, Africa, and parts of Europe.

4. Appaya Healthcare

Based in India, Appaya Healthcare specializes in the development and supply of injectable pharmaceuticals, including heparin sodium formulations.

Strengths:

  • Focused on quality control
  • Ability to supply bulk quantities
  • Certified GMP facilities

Certifications: WHO-GMP certified manufacturing, exporting mainly to Asian and African markets.

5. Kindeva Drug Delivery (formerly Tekmira)

This company offers specialized heparin products, with a focus on pharmaceutical-grade solutions suitable for hospital and clinical use.

Key features:

  • High purity heparin preparations
  • Flexibility in packaging
  • Emphasis on product stability and sterility

Supply channels: North America and select international markets.

Regulatory and Quality Considerations

Reliable suppliers for heparin sodium must meet comprehensive regulatory standards due to the product’s critical application profile. WHO-GMP, US FDA (on Form 483 compliance), EMA certification, and pharmacopoeial standards (USP, BP, EP) serve as benchmarks. Additionally, suppliers are subject to ongoing audits and quality assessments to ensure batch consistency and safety.

Challenges in Sourcing Heparin Sodium

  • Supply Chain Disruptions: Variability in porcine intestine sourcing can impact production.
  • Regulatory Scrutiny: Ongoing recalls (e.g., 2008 heparin crisis) underscore the importance of rigorous testing and traceability.
  • Pricing Volatility: Raw material price fluctuations affect market rates.

Emerging Trends and Alternatives

Advancements include synthetic or bioengineered anticoagulants, yet synthetic heparin remains in early stages. For supply continuity, diversified sourcing strategies, including multiple approved suppliers, are recommended.


Conclusion

Securing reliable suppliers of Heparin Sodium 25,000 Units in Sodium Chloride 0.45% demands diligence toward regulatory compliance, quality assurance, and supply chain robustness. Market leaders such as Baxter and Pfizer represent standard choices, while regional manufacturers like Sano Chemical Industries and Appaya Healthcare offer cost-effective alternatives, especially for emerging markets. Continuous monitoring of regulatory developments and raw material sourcing is paramount to maintain an uninterrupted supply.


Key Takeaways

  • Select suppliers with global regulatory approvals (FDA, EMA, WHO-GMP) for assured quality.
  • Consider diversified sourcing to mitigate risks from supply chain disruptions.
  • Evaluate regional manufacturers for cost-effective options while ensuring local compliance.
  • Maintain rigorous quality control and traceability standards considering product criticality.
  • Stay updated on regulatory changes and market trends to adapt procurement strategies accordingly.

Frequently Asked Questions (FAQs)

1. What are the primary regulatory considerations when sourcing heparin sodium?
Regulatory bodies require strict GMP compliance, batch testing for purity and potency, and traceability. Suppliers must adhere to standards set by FDA, EMA, and pharmacopeias to ensure safety and efficacy.

2. How does the source of heparin influence supplier choice?
Heparin sourced from porcine intestines demands rigorous quality and safety testing due to risks like viral transmission. Suppliers with validated sourcing, extraction, and purification processes are preferred.

3. Are regional manufacturers as reliable as global leaders?
Regional manufacturers can offer cost benefits and localized supply; however, due diligence regarding regulatory compliance, quality certifications, and production capacity is essential to ensure reliability.

4. What are the supply chain risks associated with heparin sodium?
Risks include raw material shortages, geopolitical issues, regulatory changes, and batch contamination. Diversifying suppliers and maintaining safety stock are vital mitigation strategies.

5. How can healthcare providers ensure product authenticity and safety?
Procure only from approved, certified suppliers. Verify batch certifications, conduct routine quality audits, and adhere to validated storage and handling protocols to safeguard patient safety.


References

  1. Baxter International Inc. Product documentation and regulatory approvals, [Baxter official website].
  2. Pfizer Inc. Health authority approvals, [Pfizer official website].
  3. Sano Chemical Industries. WHO-GMP certification details, [Company website].
  4. World Health Organization. Good Manufacturing Practices guidelines, 2022.
  5. U.S. Food & Drug Administration. Heparin supply chain safety alerts, 2008–2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.